SLC25A22 and neoplasm: 4) To explore the therapeutic value of targeting SLC25A22 in CSCC, we initially developed a novel 3D CSCC organoid that accurately recapitulates the histopathological and genetic features of parental tumors and further constructed a 3D T‐cell‐incorporated CSCC organoid model that could mimic the interaction between CD8+ T cells and tumor cells.